Compare iShares Russell 2000 ETF (IWM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Russell 2000 ETF trades at $278.99 (market cap $78.56B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 24,585,463). Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IWM | VRTX | |
|---|---|---|
Market Cap | $78.56B | $128.16B |
Volume | 24,585,463 | 806,603 |
52-Week High | $305.06 | $557.96 |
52-Week Low | $229.13 | $407.37 |
Typical Hold Time | 83 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% with bearish technical signals from moving averages and key indicators. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure emerging.
The outlook remains challenging as small-caps face tightening financial conditions and energy price pressures. Investment opportunity exists for long-term value investors seeking diversification from tech-heavy large-caps, though near-term risks include continued Fed hawkishness and weak small-cap breadth in the current market environment.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
